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 Structure of the HIV Reverse Transcriptase and 
Hepatitis B Virus DNA Polymerase 
 Structure of the HIV-1 Reverse Transcriptase 
 The HIV reverse transcriptase (RT) is a heterodimer 
composed of two subunits, p51 with the RT activity and 
p66 (p51 plus p15) which harbors mainly the catalytic ac-
tivity of ribonuclease H. The functionally active RT is an 
RNA-dependent DNA polymerase. The RT structure cor-
responds roughly to the shape of the right hand, deduced 
from the 3.5 Angström resolution electron density map of 
the crystallized enzyme  [1, 2] . The thumb is flexible, has 
close contact to the finger, and opens to process the HIV 
RNA strands  [2] . HIV particles contain two copies of HIV 
RNA and transcribe both strands during replication. The 
RT generates from the first RNA molecule the first DNA 
strand, and subsequently the first RNA strand is degraded. 
The second RNA strand used as template for the second 
DNA strand. The second RNA strand also gets degraded, 
resulting in an additional double-stranded DNA mole-
cule. By RT-shifting from one RNA strand to the second, 
recombinant viruses are formed when the cell is infected 
with two different or mutated viruses  [2] . The incoming 
dNTP (deoxynucleotide triphosphate) is moved by the 
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 Abstract 
 Coinfections with hepatitis B virus (HBV) and HIV are very 
frequent. Although HBV is a DNA virus, it replicates via re-
verse transcription like HIV. Structural similarities between 
the enzymatic pocket of the HBV DNA polymerase and HIV-1 
reverse transcriptase are the basis that certain drugs inhibit 
both enzymes and thus the replication of both viruses. HBV 
components increase the pathogenic action of HIV and vice 
versa directly by certain proteins like HBsAg in the case of 
HBV and HIV-encoded Tat and Vpr and by disturbing the cy-
tokine balance in affected cells. Antiretroviral therapy is 
highly beneficial for HIV/HBV-coinfected patients, but car-
ries the risk of drug-induced resistance development and 
hepatotoxicity. Even with restoration of the immune capac-
ity, signs of hepatic inflammation may develop even after 10 
years of treatment.  © 2014 S. Karger AG, Basel 
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fingers of the RT of HIV-1 – amino acid positions K65 
(lysine) and R72 (arginine) – and incorporated in the 
growing DNA strand. The enzymatic pocket is built by a 
loop of YMDD (tyrosine-methionine-aspartic acid-aspar-
tic acid) in positions Y183, M184, D185, and D186 (not 
shown), and by the amino acids Y115 and Q151 (gluta-
mine)  [3] – as schematically presented in  figure 1 .
 New DNA is synthesized at an approximate velocity of 
50–70 nucleotides per minute  [2] . The enzymatic ma-
chinery of HIV leads after years of infection to a virus ti-
ter of 10 4 to 10 5 per ml plasma, with a turnover rate of 
around 10 10 particles daily  [4] . The action of the RT is 
error prone since there is no proofreading activity and 
1–10 mutations may be introduced with each replication 
cycle  [4] , summing up to around 10 6 mutations per day. 
Most of the mutations are silent.
 The enzymatic pocket structure, as shown in  figure 1 , 
is very conserved and found with corresponding loop 
structures in other DNA polymerases as those of diverse 
viruses including other retroviruses, hepatitis B virus 
(HBV), and even bacteria as  Escherichia coli  [5] .
 Structure of the HBV Polymerase 
 Currently, an accurate spatial structure of the HBV 
DNA polymerase, which also harbors RNA-dependent 
DNA polymerase activity and ribonuclease H activity, is 
not available. Due to the functional similarity, the struc-
ture of the HIV RT is used for modelling the spatial struc-
ture of the HBV polymerase  [6, 7] . Comparison of HBV 
polymerase and HIV-1 RT on an amino acid sequence 
basis revealed only around 14% homologous sites  [6] , but 
the YMDD motif is conserved (HBV pol sequence posi-
tion 203–206 according to the nomenclature of Stuyver et 
al.  [8] ). The enzymatic pocket is formed by certain struc-
turally exposed amino acids (described above), which en-
able a possible identical conformation of the pockets of 
HIV-1 and HBV polymerases ( fig.  1 ). The commonly 
used drugs effective for HBV and HIV treatment are the 
nucleos(t)ide RT inhibitors (NRTI), which act by chain 
termination. Specific substances suitable for HBV and 
HIV treatment are lamivudine and tenofovir. Telbivu-
dine, adefovir, and entecavir are licensed only for HBV 
(see van Bömmel [this issue, pp. 171–180]).
 As described for the HIV-1 RT, the M204V or I muta-
tion in the YMDD motif of HBV results in complete re-
sistance against lamivudine and emtricitabine  [6] . The 
prominent amino acids that build the enzymatic pocket 
of the HBV RT are in relation to HIV-1 as shown in  fig-
ure 1 : D19 (in yellow instead of K65 in HIV) in the upper 
left part, M160 in the motif PM(160)G in HBV and 
PQ(151)G in HIV in the lower left part, M204 in yellow 
the lower right part, and finally L229 in the upper right 
 Fig. 1. Scheme of the enzymatic pockets of HIV-1 (left) and HBV 
(right). The methionine (M) of the highly conserved YMDD motif 
is shown hatched in HIV as M184 and in HBV as M204. In the left 
part of the pocket, the K65 (lysine, also hatched) position may be 
seen which mutates to K65R (arginine) yielding tenofovir resis-
tance in HIV. This amino acid is replaced in the HBV polymerase 
by an aspartic acid (D19). In the center of the pocket is the growing 






part. HBV L180, which is selected as a compensatory mu-
tation to M204V or I, does not have a corresponding ami-
no acid in the HIV-1 sequence.
 In a patient with chronic hepatitis B, 10 12 HBV parti-
cles are produced and eliminated daily  [7] . Assuming a 
mutation rate of 10 –5 per cycle within the process of HBV 
RT, sufficient mutations could be generated leading to 
rapid drug resistance as found in HIV monotherapy. 
However, since the HBV genome is condensed and uses 
overlapping reading frames, mutations in the RT open 
reading frame must be tolerated as well in the preS/S open 
reading frame; thus, many of the theoretically possible 
mutations are not viable. However, lamivudine resistance 
of HBV develops very often at a rate of around 14–24% 
per year  [7] , while clinically relevant tenofovir resistance 
has not been found after >10 years of drug therapy of 
hepatitis B.
 Pathogenicity 
 Major Targets of HIV-1 Pathogenicity 
 There are multiple factors and potential therapeutic 
targets for HIV pathogenicity  [9] ; however, only parts of 
those HIV-1 proteins that interact with the HBV replica-
tion cycle are shortly described here. Generally HIV-1 in-
fection worsens the course of hepatitis B and HBV patho-
genicity more than vice versa  [10] . The main HIV pro-
teins for activation of the cell metabolism and viral 
turnover, Tat, Vpr, and gp120, are released from HIV-
infected cells and are detectable in the plasma of AIDS 
patients  [11] . They are taken up by several cell types, in-
cluding hepatocytes and accelerate the pathogenic action 
of HBV like induction of fibrosis and hepatocellular car-
cinoma  [12, 13] . Nef downregulates CD4 and HLA mol-
ecules in HIV-infected cells and induces by this action a 
 Fig. 2. Scheme of the interactions of HBV and HIV-1, either by the 
virus itself or by viral proteins that enhance immunosuppression 
and accelerate viral turnover and thus increase pathogenicity  [30] . 
e-protein = HBeAg; s-protein = HB surface Ag; x-protein = HBx 
protein; gp120 = HIV-1 surface glycoprotein with a molecular 
weight of 120.000; Nef = negative regu lating factor; Tat = tran-
scription-mediated transactivator, Vpr = viral protein R; HCC = 
hepatocellular carcinoma. All viral proteins may be found inside 
and outside of a cell. 
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certain degree of immune incompetence on a cell-cell co-
operation level  [14] . This is supported by the toxic action 
of Tat on T lymphocytes, which in the beginning leads to 
activation of the cell metabolism. In the long term, Tat 
activation of lymphocytes and hepatic cells is followed by 
exhaustion and finally apoptosis  [11, 15] . HIV itself is cy-
totoxic and leads to lysis of the infected cell, partially as-
sociated with giant cell formation. A scheme of this HBV 
and HIV-1 component interaction is shown in  figure 2 .
 The destruction of helper T lymphocytes by virus re-
lease, viral components, cytotoxic T cell-mediated immu-
nity, antibody-dependent cellular cytotoxicity, and im-
paired restoration of lost helper T lymphocytes are spe-
cific for HIV pathogenicity  [9] . The weakened immune 
function hampers the inhibition of HBV replication from 
the covalently closed circular DNA form in the nuclei of 
hepatocytes and generate HBV and cellular components, 
such as IL-10, which further support the immunosup-
pressive action.
 Major Targets of HBV Pathogenicity 
 While HIV itself is cytotoxic for T lymphocytes, HBV 
usually does not induce liver cell cytotoxicity by itself. He-
patocyte destruction and associated clinical signs of hep-
atitis are dependent on the function of the host immune 
system. Necrosis of hepatocytes is accomplished by 
primed cytotoxic T lymphocytes, and antibody-depen-
dent cellular cytotoxicity  [16] . Under insufficient im-
mune control, HBV titers in blood will increase, as will 
the concentration of HBsAg and HBeAg and potentially 
the HBx protein. When the HIV-induced immunodefi-
ciency improves under antiretroviral treatment, symp-
toms of hepatitis may aggravate severely – a phenomenon 
described under immune reconstitution inflammatory 
syndrome  [4, 10] . HBV induces the liberation of IL-10, 
which has an immunosuppressive action by inhibiting 
the production of interferon (IFN)-γ and stimulating cy-
tokines such as IL-2, IL-3, and TNF-α  [17] , and by inhib-
iting IFN-α production, which supports apoptosis of den-
dritic cells  [16] .
 HBV proteins disturb the host immune function in 
several ways. In monocytes, dendritic cells, and Kupffer 
cells, HBsAg inhibits the synthesis of IL-12, which itself 
stimulates the production of IFN-γ; therefore, HBsAg 
acts in an immunosuppressive manner  [17] . HBeAg sup-
presses IFN-β and TNF-α synthesis, and thus leads to im-
paired immune function  [17] . The HBx protein inhibits 
the synthesis of IFN-β  [17] . As mentioned above, the HBx 
protein enhances RNA transcription in the HIV-1 long 
terminal repeat, which leads to higher HIV replication 
and sustains the immune dysfunction through the action 
of HIV-1 components  [18, 19] . Finally, the HBx protein 
may enhance liver disease progression associated with 
cell fibrosis and (after decades) cirrhosis and tumorigen-
esis (hepatocellular carcinoma)  [12] .
 Copathogenicity of HBV and HIV-1 
 HBV may be cleared from blood and body fluids by the 
function of an intact immune system; therefore, clinically 
typical signs of liver disease are not apparent in around 
85–95% of infected patients. However, the virus remains 
persistently in the liver cell due to the high stability of the 
HBV covalently closed circular DNA. HIV causes perma-
nent infection after the proviral DNA has been integrated 
in the host cell genome of T-helper lymphocytes, macro-
phages, and microglia cells. Both viruses induce immu-
nodeficiency. HIV acts directly by impairing the function 
of T-helper lymphocytes, and by their destruction until in 
some AIDS patients their total depletion occurs. HBV 
acts more subtly by secretion of the proteins HBsAg, 
HBeAg, and potentially HBx, which may act themselves 
tolerogenic or even immunosuppressive and strengthen 
the HIV-induced immunodeficiency  [10] . Unfortunate-
ly, the HIV-associated immunodeficiency is neither suf-
ficient to block immune pathogenesis of hepatitis B, nor 
to interfere with the pathogenic action of HBV and HIV 
components on the cytokine cascades. Thus, HIV-1 wors-
ens the outcome of chronic hepatitis B and, on a cellular 
level, enhances its own replication and that of HBV. The 
higher viral burden is associated with higher toxicity and 
extended pathogenicity. The vicious cycle can be inter-
rupted by a selected antiretroviral treatment which ham-
pers replication of both viruses and, finally, has the po-
tential to stop virus production  [20] .
 Treatment of HIV-1/HBV-Coinfected Patients with 
NRTI 
 Only NRTI are active against HBV. Non-NNRTI will 
not block the activity of the HBV polymerase by changing 
the substrate binding site of the enzymatic pocket as in 
HIV-1 RT  [4] . Substances that inhibit the HIV protease 
or integrase cannot be used since both enzymes are absent 
in HBV.
 The first HBV drug used was lamivudine (3TC) which 
is no longer recommended due to frequent (around 20% 
per year) mutations in M204V/I causing resistance  [21] . 
A specific problem was that lamivudine remained active 
against HIV due to the combination therapy, while
HBV – treated only with lamivudine – became rapidly 






were developed and today the preference to treat HIV-1/
HBV is the combination of tenofovir plus emtricitabine 
since no HBV drug resistance has been detected in the 
patients after 10 years of application  [22] . However, te-
nofovir treatment is possibly less effective in HIV pa-
tients coinfected with HBV genotype G after pretreat-
ment with lamivudine  [23] . Long-term tenofovir expo-
sure might reduce kidney function in 63% of the treated 
patients  [24] . A further side effect is that a combination 
of various ART drugs given to suppress the replication of 
HIV-1 in a chronic hepatitis B patient may lead to dead-
ly acute liver failure due to severe hepatotoxicity  [25] . 
Treatment of a recently coinfected patient shortly after 
HIV-1 seroconversion doubles the hazard for an AIDS 
or death event  [26] , indicating that not all of the patho-
genic interactions of HBV and HIV-1 coinfection are 
known.
 Influence of Host Factors 
 Finally, there are several host genetic factors (not dis-
cussed in this article) that influence the course of the dis-
ease, such as CCR5Δ32, a mutation in the CCR5 (chemo-
kine receptor 5), the coreceptor for HIV entry, and SNPs 
in the HBV receptor sodium-dependent taurocholic co-
transporting polypeptide, which is a G7 protein  [27, 28] 
spanning the cell membrane as CCR5. Additionally, both 
HIV and HBV RNA stability are partially controlled by 
the APOBEC3 system.
 Future Aspects 
 There are two ways to influence the outcome of pa-
tients infected with HBV and HIV: the development of 
new drugs and vaccination to prevent infection.
 New Drugs 
 Inhibition of the HBV polymerase is achieved usually 
at lower drug concentrations than necessary for the inhi-
bition of the action of the HIV RT. Nearly all of the drugs 
used today for HBV treatment were initially developed 
for HIV, including the combination of tenofovir plus em-
tricitabine, which is as effective as tenofovir monotherapy 
for the long-term treatment of hepatitis B  [22] . The main 
restriction of the present tenofovir therapy is still hepato-
toxicity  [29] and nephrotoxicity  [24] . As shown for the 
inhibition of HCV enzymes, there is a high pharmaceuti-
cal potential to design new drugs, which should open 
some aspects for a better quality of life and outcome of 
coinfected patients.
 Vaccination 
 The immune reaction against HBV induces clinical 
resolution of hepatitis B and control of the occult intra-
hepatic HBV in around 85–95% of those with natural in-
fection  [30] . HBV childhood vaccination, and with a 
somewhat lower efficacy adulthood vaccination, has been 
shown to protect against HBV disease and HBV chronic-
ity after exposure. Thus, extended HBV vaccination of a 
population will limit the spread of HBV. Complications 
of chronic hepatitis B like liver fibrosis, cirrhosis, and 
HCC are absent in successfully vaccinated persons. There 
are still the limitations of HBV escape variants and im-
munological failure in around 5% of those vaccinated to 
produce a sufficient amount of anti-HBs.
 An effective vaccine against HIV-1 or HIV-2 does not 
exist and, according to all the trials performed over the 
last 30 years, will be very hard to design. Thus, the pres-
ence and spread of HIV in certain parts of a population 
will persist while the circulation of HBV can be reduced 
to a very low level.
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